Expert Interview
Digging into the results from the P3 CORAL study of Biogen and Sage Therapeutics' Zuranolone in patients with major depressive disorder before PDUFA on Aug 5th
Ticker(s): SAGE, BIIBInstitution: University of Pennsylvania
- Professor of Psychiatry at the Perelman School of Medicine
- Research interests include genetics, pharmacogenetics and medical treatment of addictions, mood disorders, schizophrenia, and epilepsy
- The Berrettini Lab is currently studying single cell transcriptomics in neurons and glia as potential causative factors in risk for addictions, psychotic illnesses, and mood disorders.
From a high-level view with all the data Zuranolone has shown so far, what is your opinion on this drug and its potential?
In terms of the CORAL study where they looked at the drug in combination with antidepressant therapy, and they showed an improvement over a placebo, what were your impressions of that data?
When you think about the role of this drug in the treatment of depression, do you think it will be in conjunction with other antidepressants or as a monotherapy?
What percent of your patients do you think you would be giving this drug to, if it is approved?
In terms of a percentage of your MDD patients, which ones would be good candidates for this?
How do you interpret the data showing separation at day three from the control arm, and that continued at day eight and day twelve, but then at day fifteen, the curves got much closer?
Does the fact that from day fifteen onwards, you're not really getting all the differences in that first few days take away from the utility of Zuranolone? Would that still be appealing?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
